Eric Solary

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6524965/publications.pdf

Version: 2024-02-01

368 papers	32,648 citations	3933 88 h-index	5120 166 g-index
391 all docs	391 docs citations	391 times ranked	37076 citing authors

#	Article	IF	Citations
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	7.2	1,211
2	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 2007, 56, 641-648.	4.2	1,104
3	Hsp27 negatively regulates cell death by interacting with cytochrome c. Nature Cell Biology, 2000, 2, 645-652.	10.3	882
4	CD4⁺CD25⁺ regulatory Tâ€„cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. European Journal of Immunology, 2004, 34, 336-344.	2.9	846
5	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	16.8	792
6	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. Journal of Clinical Investigation, 2010, 120, 457-71.	8.2	761
7	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. Blood, 1999, 94, 1192-1200.	1.4	682
8	Tumor cells convert immature myeloid dendritic cells into TGF-Î²â€“secreting cells inducing CD4+CD25+ regulatory T cell proliferation. Journal of Experimental Medicine, 2005, 202, 919-929.	8.5	676
9	Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.. Journal of Clinical Oncology, 1997, 15, 139-147.	1.6	670
10	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
11	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. Immunity, 2013, 38, 729-741.	14.3	572
12	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	1.6	462
13	HSP27 inhibits cytochrome câ€dependent activation of procaspaseâ€9. FASEB Journal, 1999, 13, 2061-2070.	0.5	453
14	Induction of a Common Pathway of Apoptosis by Staurosporine. Experimental Cell Research, 1994, 211, 314-321.	2.6	451
15	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO Journal, 2013, 32, 645-655.	7.8	411
16	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood, 2015, 126, 1106-1117.	1.4	399
17	Heat shock proteins: essential proteins for apoptosis regulation. Journal of Cellular and Molecular Medicine, 2008, 12, 743-761.	3.6	391
18	Caspase Activation Is Required for Terminal Erythroid Differentiation. Journal of Experimental Medicine, 2001, 193, 247-254.	8.5	387

#	Article	IF	Citations
19	ERCC1 Isoform Expression and DNA Repair in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2013, 368, 1101-1110.	27.0	342
20	Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochemical and Biophysical Research Communications, 2003, 304, 505-512.	2.1	321
21	HSP27 Is a Ubiquitin-Binding Protein Involved in I-ÎºBÎ± Proteasomal Degradation. Molecular and Cellular Biology, 2003, 23, 5790-5802.	2.3	301
22	Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells. Cancer Research, 2004, 64, 3593-3598.	0.9	293
23	Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. Molecular and Cellular Biology, 2006, 26, 7046-7055.	2.3	288
24	Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood, 2002, 100, 4446-4453.	1.4	287
25	Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs. Journal of Biological Chemistry, 1999, 274, 7987-7992.	3.4	282
26	Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity. Journal of the National Cancer Institute, 1997, 89, 783-789.	6.3	273
27	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
28	Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature, 2007, 445, 102-105.	27.8	246
29	Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells. Journal of Biological Chemistry, 2003, 278, 41482-41490.	3.4	241
30	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia, 2014, 28, 2206-2212.	7.2	237
31	The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia, 2014, 28, 485-496.	7.2	235
32	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	3.5	234
33	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood, 2010, 115, 1690-1696.	1.4	232
34	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	1.4	232
35	Essential role for the p110Â isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood, 2005, 106, 1063-1066.	1.4	229
36	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010, 24, 1094-1096.	7.2	225

#	Article	IF	Citations
37	Tumor cells can escape DNAâ€damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biology International, 2008, 32, 1031-1043.	3.0	213
38	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. Cancer Discovery, 2014, 4, 1088-1101.	9.4	213
39	Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. Cancer Investigation, 1994, 12, 530-542.	1.3	204
40	Vital functions for lethal caspases. Oncogene, 2005, 24, 5137-5148.	5.9	202
41	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 2015, 125, 3618-3626.	1.4	197
42	Glutathione is implied in the control of 7â€ketocholesterolâ€induced apoptosis, which is associated with radical oxygen species production. FASEB Journal, 1998, 12, 1651-1663.	0.5	192
43	Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. Journal of Experimental Medicine, 2005, 201, 465-471.	8.5	191
44	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood, 2011, 118, 3824-3831.	1.4	187
45	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23, 8979-8986.	5.9	181
46	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	12.8	177
47	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	1.4	169
48	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood, 2011, 118, 2551-2555.	1.4	163
49	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. Journal of Clinical Investigation, 2014, 124, 580-591.	8.2	163
50	Circulating Immature Granulocytes With T-Cell Killing Functions Predict Sepsis Deterioration*. Critical Care Medicine, 2014, 42, 2007-2018.	0.9	156
51	A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. Leukemia, 2013, 27, 2187-2195.	7.2	154
52	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	1.4	153
53	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2015, 125, 1857-1872.	8.2	151
54	TRAIL in cancer therapy: present and future challenges. Expert Opinion on Therapeutic Targets, 2007, 11, 1299-1314.	3.4	148

#	Article	IF	Citations
55	Small Heat Shock Proteins HSP27 and Î±B-Crystallin: Cytoprotective and Oncogenic Functions. Antioxidants and Redox Signaling, 2005, 7, 404-413.	5.4	144
56	Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe. Current Medicinal Chemistry, 2011, 18, 1100-1121.	2.4	144
57	Heat Shock Protein 70 Neutralization Exerts Potent Antitumor Effects in Animal Models of Colon Cancer and Melanoma. Cancer Research, 2006, 66, 4191-4197.	0.9	138
58	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia, 2014, 28, 338-348.	7.2	137
59	Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene, 2000, 19, 4855-4863.	5.9	135
60	FAS-L, IL-10, and double-negative CD4â^'CD8â^' TCR Î±/Î²+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood, 2009, 113, 3027-3030.	1.4	134
61	Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia, 2000, 14, 1833-1849.	7.2	131
62	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp>ayo <scp>C</scp>linicâ€<scp>F</scp>rench <scp>C</scp>onsortium <scp>S</scp>tudy. American Journal of Hematology, 2014, 89, 1111-1115.	4.1	129
63	Human defensins as cancer biomarkers and antitumour molecules. Journal of Proteomics, 2009, 72, 918-927.	2.4	128
64	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	2.5	127
65	Caspase-8 prevents sustained activation of NF-ÎºB in monocytes undergoing macrophagic differentiation. Blood, 2007, 109, 1442-1450.	1.4	125
66	Autophagy is required for CSF-1â€“induced macrophagic differentiation and acquisition of phagocytic functions. Blood, 2012, 119, 4527-4531.	1.4	123
67	Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoroâ€uracil sensitivity in human derived colon cancer cells. International Journal of Cancer, 2009, 124, 2780-2788.	5.1	122
68	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNÎ±. Blood, 2013, 122, 1464-1477.	1.4	122
69	Apoptosis and Its Modulation in Human Promyelocytic HL-60 Cells Treated with DNA Topoisomerase I and II Inhibitors. Experimental Cell Research, 1993, 207, 388-397.	2.6	118
70	Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene, 2003, 22, 1807-1816.	5.9	117
71	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal, 2015, 5, e333-e333.	6.2	117
72	Turning the tide in myelodysplastic/myeloproliferative neoplasms. Nature Reviews Cancer, 2017, 17, 425-440.	28.4	117

#	Article	IF	Citations
73	A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Molecular Cancer Therapeutics, 2007, 6, 2337-2345.	4.1	114
74	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research, 2020, 26, 242-255.	7.0	114
75	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 2021, 12, 258.	6.3	113
76	Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2014, 32, 297-305.	1.6	109
77	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 2015, 47, 1131-1140.	21.4	107
78	Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica, 2011, 96, 612-616.	3.5	106
79	Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clinical and Experimental Immunology, 2007, 150, 523-530.	2.6	104
80	JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene, 2012, 31, 1323-1333.	5.9	104
81	Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.. Journal of Clinical Oncology, 1992, 10, 1730-1736.	1.6	103
82	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	4.6	103
83	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	7.2	102
84	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 1117-1130.	3.5	97
85	Induction of Transglutaminase 2 by a Liver X Receptor/Retinoic Acid Receptor Î± Pathway Increases the Clearance of Apoptotic Cells by Human Macrophages. Circulation Research, 2009, 105, 393-401.	4.5	96
86	HSP27 favors ubiquitination and proteasomal degradation of p27 Kip1 and helps Sâ€phase reâ€entry in stressed cells. FASEB Journal, 2006, 20, 1179-1181.	0.5	95
87	Extracellular HSP27 mediates angiogenesis through Tollâ€like receptor 3. FASEB Journal, 2013, 27, 4169-4183.	0.5	93
88	How I treat chronic myelomonocytic leukemia. Blood, 2017, 130, 126-136.	1.4	93
89	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. Blood, 1998, 91, 2415-2422.	1.4	92
90	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere, 2018, 2, e150.	2.7	91

#	Article	IF	Citations
91	Transcription intermediary factor 1Î³ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. Journal of Clinical Investigation, 2011, 121, 2361-2370.	8.2	91
92	Efficacy and tolerance of an amphotericm B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. Journal of Antimicrobial Chemotherapy, 1993, 31, 161-169.	3.0	89
93	Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate. Cell Death and Differentiation, 1998, 5, 480-487.	11.2	88
94	Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia, 2015, 29, 249-252.	7.2	88
95	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood, 2015, 125, 930-940.	1.4	87
96	p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene, 1999, 18, 1411-1418.	5.9	86
97	Transactivation of the Epidermal Growth Factor Receptor by Heat Shock Protein 90 via Toll-like Receptor 4 Contributes to the Migration of Glioblastoma Cells. Journal of Biological Chemistry, 2011, 286, 3418-3428.	3.4	86
98	Endocytosis of Resveratrol via Lipid Rafts and Activation of Downstream Signaling Pathways in Cancer Cells. Cancer Prevention Research, 2011, 4, 1095-1106.	1.5	86
99	The PRKAA1/AMPKÎ±1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. Autophagy, 2015, 11, 1114-1129.	9.1	86
100	Mitochondria in hematopoiesis and hematological diseases. Oncogene, 2006, 25, 4757-4767.	5.9	85
101	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS ONE, 2017, 12, e0188174.	2.5	85
102	Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene, 1999, 18, 4839-4847.	5.9	84
103	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood, 2003, 102, 1202-1210.	1.4	84
104	The Viral Nucleocapsid Protein of Transmissible Gastroenteritis Coronavirus (TGEV) Is Cleaved by Caspase-6 and -7 during TGEV-Induced Apoptosis. Journal of Virology, 2000, 74, 3975-3983.	3.4	83
105	An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia, 2013, 27, 1441-1450.	7.2	81
106	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene, 2001, 20, 1852-1859.	5.9	80
107	A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 1994, 33, 603-613.	3.0	79
108	Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood, 2001, 97, 3931-3940.	1.4	79

#	Article	IF	Citations
109	Cohen syndrome is associated with major glycosylation defects. Human Molecular Genetics, 2014, 23, 2391-2399.	2.9	79
110	Apoptosis Induced by DNA Topoisomerase I and II Inhibitors in Human Leukemic HL-60 Cells. Leukemia and Lymphoma, 1994, 15, 21-32.	1.3	78
111	Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. British Journal of Haematology, 1998, 102, 1015-1024.	2.5	78
112	Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene, 2001, 20, 7478-7485.	5.9	77
113	Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. Oncogene, 1998, 16, 2885-2894.	5.9	75
114	Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death and Differentiation, 2011, 18, 700-711.	11.2	75
115	Imaging of nitric oxide in a living vertebrate using a diaminofluorescein probe. Free Radical Biology and Medicine, 2007, 43, 619-627.	2.9	74
116	Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway. Journal of Immunology, 2000, 164, 5023-5027.	0.8	72
117	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	6.1	72
118	Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology, 2002, 123, 235-246.	1.3	71
119	Proteases, proteolysis, and apoptosis. Cell Biology and Toxicology, 1998, 14, 121-132.	5.3	70
120	Applying ecological and evolutionary theory to cancer: a long and winding road. Evolutionary Applications, 2013, 6, 1-10.	3.1	70
121	MOZ/TIF2â€induced acute myeloid leukaemia in transgenic fish. British Journal of Haematology, 2008, 143, 378-382.	2.5	69
122	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood, 2014, 123, 1372-1383.	1.4	69
123	CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Scientific Reports, 2016, 6, 37827.	3.3	69
124	High Concentrations of Intrathecal Interleukin-6 in Human Bacterial and Nonbacterial Meningitis. Journal of Infectious Diseases, 1992, 166, 428-431.	4.0	68
125	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood, 2012, 120, 2719-2722.	1.4	68
126	Developmental changes in human megakaryopoiesis. Journal of Thrombosis and Haemostasis, 2013, 11, 1730-1741.	3.8	68

#	Article	IF	Citations
127	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer Journal, 2017, 7, e584-e584.	6.2	68
128	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€"a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	7.2	68
129	The role of apoptosis in the pathogenesis and treatment of diseases. European Respiratory Journal, 1996, 9, 1293-1305.	6.7	66
130	HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood, 2010, 116, 85-96.	1.4	66
131	Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis. Oncotarget, 2016, 7, 28160-28168.	1.8	66
132	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia, 2019, 33, 2466-2480.	7.2	66
133	Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. American Journal of Hematology, 1992, 39, 163-171.	4.1	65
134	Comparative analysis of zebrafish nos2a and nos2b genes. Gene, 2009, 445, 58-65.	2.2	63
135	Prophylactic Fluconazole andCandida kruseiInfections. New England Journal of Medicine, 1992, 326, 891-893.	27.0	62
136	Apoptotic Topoisomerase I-DNA Complexes Induced by Staurosporine-mediated Oxygen Radicals. Journal of Biological Chemistry, 2004, 279, 50499-50504.	3.4	62
137	STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated with Cytotoxic Drugs. Biochemical and Biophysical Research Communications, 1999, 256, 603-607.	2.1	61
138	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood, 2012, 119, 1532-1542.	1.4	61
139	Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System. Journal of Immunology, 2001, 167, 5077-5083.	0.8	60
140	Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells. Molecular Cancer Research, 2004, 2, 53-61.	3.4	60
141	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. Journal of Immunology, 2010, 184, 1876-1884.	0.8	58
142	Identifying key questions in the ecology and evolution of cancer. Evolutionary Applications, 2021, 14, 877-892.	3.1	58
143	Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. Blood, 2001, 97, 1835-1844.	1.4	57
144	TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT. PLoS ONE, 2011, 6, e19679.	2.5	57

#	Article	IF	Citations
145	The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. Cell Death and Disease, 2014, 5, e1533-e1533.	6.3	57
146	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation, 2008, 118, 3751-3761.	8.2	56
147	Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood, 2004, 104, 2035-2043.	1.4	55
148	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	12.8	55
149	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 2017, 130, 832-835.	1.4	55
150	Identification of Proteins Cleaved Downstream of Caspase Activation in Monocytes Undergoing Macrophage Differentiation*. Journal of Biological Chemistry, 2006, 281, 17779-17788.	3.4	53
151	Editorial: CSF1R, CSF-1, and IL-34, a â€œmÃ©nage Ã troisâ€•conserved across vertebrates. Journal of Leukocyte Biology, 2010, 87, 745-747.	3.3	53
152	CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. Cell Death and Disease, 2012, 3, e396-e396.	6.3	53
153	Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia, 2001, 15, 1572-1581.	7.2	52
154	Colony-stimulating factor-1â€“induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. Blood, 2009, 114, 3633-3641.	1.4	51
155	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98, 1748-1752.	3.5	50
156	NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. Cell Death and Differentiation, 2017, 24, 1632-1644.	11.2	50
157	Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochemical Pharmacology, 1993, 45, 2449-2456.	4.4	49
158	Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. Cell Death and Differentiation, 1999, 6, 351-361.	11.2	49
159	A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia, 1999, 13, 524-529.	7.2	49
160	The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene, 2003, 22, 935-946.	5.9	49
161	A role of HSPs in apoptosis through â€œprotein triageâ€?. Cell Death and Differentiation, 2003, 10, 619-620.	11.2	48
162	Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene, 2010, 29, 5019-5031.	5.9	48

#	Article	IF	Citations
163	Cellular localisation of Survivin: impact on the prognosis in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2005, 131, 504-510.	2.5	46
164	Caspase-2, a Novel Lipid Sensor under the Control of Sterol Regulatory Element Binding Protein 2. Molecular and Cellular Biology, 2005, 25, 9621-9631.	2.3	46
165	Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 722-725.	2.9	45
166	Interaction of heat-shock protein 90Î² isoform (HSP90Î²) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death and Differentiation, 2008, 15, 859-866.	11.2	45
167	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood, 2011, 117, 3065-3075.	1.4	45
168	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood, 2014, 124, 2104-2115.	1.4	45
169	Casein Kinase II-mediated Phosphorylation of NF-ÎºB p65 Subunit Enhances Inducible Nitric-oxide Synthase Gene Transcription in Vivo. Journal of Biological Chemistry, 2004, 279, 23953-23960.	3.4	44
170	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood, 2010, 115, 78-88.	1.4	44
171	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	12.8	44
172	Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. Leukemia, 1998, 12, 34-43.	7.2	43
173	A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1936-1946.	4.1	43
174	Role of Tumor Cell Apoptosis in Tumor Antigen Migration to the Draining Lymph Nodes. Journal of Immunology, 2000, 164, 1995-2000.	0.8	42
175	Mitochondria as a Target for Inducing Death of Malignant Hematopoietic Cells. Leukemia and Lymphoma, 2003, 44, 563-574.	1.3	42
176	Differential Mechanisms of Conjunctival Cell Death Induction by Ultraviolet Irradiation and Benzalkonium Chloride. , 2006, 47, 4221.		42
177	The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene, 2010, 29, 2577-2584.	5.9	42
178	Transfer of functional microRNAs between glioblastoma and microvascular endothelial cells through gap junctions. Oncotarget, 2016, 7, 73925-73934.	1.8	42
179	Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells. Oncotarget, 2017, 8, 37681-37693.	1.8	41
180	Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer, 1991, 68, 1714-1719.	4.1	40

#	Article	IF	Citations
181	Caffeine Sensitizes Human H358 Cell Line to p53-mediated Apoptosis by Inducing Mitochondrial Translocation and Conformational Change of BAX Protein. Journal of Biological Chemistry, 2001, 276, 38980-38987.	3.4	40
182	Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription. Journal of Biological Chemistry, 2011, 286, 26406-26417.	3.4	40
183	Fine-tuning nucleophosmin in macrophage differentiation and activation. Blood, 2011, 118, 4694-4704.	1.4	39
184	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 2015, 5, e270-e270.	6.2	39
185	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia, 2019, 33, 205-216.	7.2	39
186	Proper macrophagic differentiation requires both autophagy and caspase activation. Autophagy, 2012, 8, 1141-1143.	9.1	38
187	CMML: Clinical and molecular aspects. International Journal of Hematology, 2017, 105, 711-719.	1.6	38
188	Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene, 2001, 20, 260-269.	5.9	36
189	Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1513-1524.	4.9	36
190	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. American Journal of Hematology, 2014, 89, 604-609.	4.1	36
191	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood, 2016, 127, 749-760.	1.4	36
192	Non-apoptotic functions of caspases in myeloid cell differentiation. Cell Death and Differentiation, 2017, 24, 1337-1347.	11.2	36
193	Primary tumor- and metastasis-derived colon cancer cells differently modulate connexin expression and function in human capillary endothelial cells. Oncotarget, 2015, 6, 28800-28815.	1.8	36
194	Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. , 1998, 77, 796-802.		35
195	Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism. Journal of Immunology, 2007, 179, 812-818.	0.8	35
196	cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand. Blood, 2009, 113, 175-185.	1.4	35
197	Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia, 2013, 27, 1946-1949.	7.2	35
198	Diagnostic value of serum ILâ€6 level in monoclonal gammopathies. British Journal of Haematology, 1995, 89, 243-249.	2.5	34

#	Article	IF	Citations
199	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. Stem Cells, 2014, 32, 2084-2097.	3.2	34
200	The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. Blood Advances, 2017, 1, 1959-1976.	5.2	34
201	Towards a classification ofÂstemÂcells. ELife, 2019, 8, .	6.0	34
202	Dobutamine Stress Echocardiography Identifies Anthracycline Cardiotoxicity. European Journal of Echocardiography, 2000, 1, 180-183.	2.3	33
203	A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly. PLoS ONE, 2011, 6, e29058.	2.5	33
204	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. Nature Communications, 2018, 9, 5455.	12.8	33
205	Towards a cancer mission in Horizon Europe: recommendations. Molecular Oncology, 2020, 14, 1589-1615.	4.6	33
206	Correlation of MDR1 /Pâ€170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. European Journal of Haematology, 1992, 48, 254-258.	2.2	32
207	Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS ONE, 2013, 8, e74257.	2.5	32
208	A role for peroxisome proliferatorâ€activated receptor gamma in resveratrolâ€induced colon cancer cell apoptosis. Molecular Nutrition and Food Research, 2014, 58, 1785-1794.	3.3	32
209	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. Blood, 2019, 133, 2718-2724.	1.4	31
210	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	11.2	31
211	Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells. Anti-Cancer Agents in Medicinal Chemistry, 2003, 3, 307-318.	7.0	31
212	Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. Cancer Research, 2002, 62, 1815-21.	0.9	31
213	Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia, 2000, 14, 2085-2094.	7.2	30
214	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death and Disease, 2013, 4, e738-e738.	6.3	30
215	Dual regulation of SPI1/PU.1 transcription factor by heat shock factor 1 (HSF1) during macrophage differentiation of monocytes. Leukemia, 2014, 28, 1676-1686.	7.2	30
216	Resveratrol stimulates the metabolic reprogramming of human CD4 ⁺ T cells to enhance effector function. Science Signaling, 2017, 10, .	3.6	29

#	Article	IF	Citations
217	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. Drug Development Research, 1995, 34, 138-144.	2.9	28
218	Nitric Oxide-Induced Down-Regulation of Î²-Catenin in Colon Cancer Cells by a Proteasome-Independent Specific Pathway. Gastroenterology, 2006, 131, 1142-1152.	1.3	28
219	Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene, 2006, 25, 7635-7645.	5.9	28
220	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. Cell Reports, 2019, 28, 3381-3394.e7.	6.4	28
221	Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. British Journal of Cancer, 1990, 62, 395-397.	6.4	27
222	Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1586, 233-242.	3.8	27
223	Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Letters, 2002, 185, 181-189.	7.2	27
224	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia, 2008, 22, 1864-1873.	7.2	27
225	A role for caspases in the differentiation of erythroid cells and macrophages. Biochimie, 2008, 90, 416-422.	2.6	27
226	Targeting apoptosis proteins in hematological malignancies. Cancer Letters, 2013, 332, 325-334.	7.2	27
227	Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell Death and Differentiation, 2005, 12, 687-689.	11.2	26
228	Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia, 2012, 26, 2297-2299.	7.2	25
229	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget, 2017, 8, 54082-54095.	1.8	25
230	Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. Blood Advances, 2017, 1, 972-979.	5.2	25
231	Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages. Nature Communications, 2019, 10, 1935.	12.8	25
232	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	1.4	25
233	Subcellular Expression of c-IAP1 and c-IAP2 in Colorectal Cancers: Relationships with Clinicopathological Features and Prognosis. Pathology Research and Practice, 2003, 199, 723-731.	2.3	24
234	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer Journal, 2018, 8, 82.	6.2	24

#	Article	IF	Citations
235	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial. Blood, 2020, 136, 53-54.	1.4	24
236	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood, 2022, 139, 1066-1079.	1.4	24
237	Der(16)t(l;16)(qll;qll) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenic and fluorescence in situ hybridization studies. British Journal of Haematology, 1995, 90, 119-124.	2.5	23
238	Cancer: an emergent property of disturbed resourceâ€rich environments? Ecology meets personalized medicine. Evolutionary Applications, 2015, 8, 527-540.	3.1	23
239	Radiolabeling of DNA can induce its fragmentation in HL-60 human promyelocytic leukemic cells. Experimental Cell Research, 1992, 203, 495-498.	2.6	22
240	cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation. Oncogene, 2014, 33, 5534-5545.	5.9	22
241	PreB1 (CD10⁻) Acute Lymphoblastic Leukemia: Immunophenotypic and Genomic Characteristics, Clinical Features and Outcome in 38 Adults and 26 Children. Leukemia and Lymphoma, 1998, 28, 329-342.	1.3	21
242	Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. , 2000, 86, 827-834.		21
243	Liver X Receptorâ€“Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1923-1929.	2.4	21
244	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. Seminars in Arthritis and Rheumatism, 2020, 50, 879-884.	3.4	21
245	Bone Marrow Necrosis and Human Parvovirus Associated Infection Preceding an Phl + Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1992, 8, 415-419.	1.3	20
246	The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. Oncogene, 2016, 35, 2842-2851.	5.9	20
247	DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues. Cell Death and Disease, 2017, 8, e2816-e2816.	6.3	20
248	Freshly isolated bone marrow cells induce death of various carcinoma cell lines. International Journal of Cancer, 2003, 107, 747-756.	5.1	19
249	Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state. Haematologica, 2020, 105, e147-e152.	3.5	19
250	Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. Oncotarget, 2012, 3, 1284-1293.	1.8	19
251	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. British Journal of Haematology, 2000, 111, 801-806.	2.5	18
252	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. European Journal of Cancer, 2018, 103, 108-119.	2.8	18

#	Article	IF	Citations
253	DISSEMINATED ASPERGILLOSIS REVEALED BY THYROIDITIS IN A RENAL ALLOGRAFT RECIPIENT. Transplantation, 1987, 44, 839.	1.0	17
254	Increased Immunogenicity of Colon Cancer Cells by Selective Depletion of Cytochrome c. Cancer Research, 2004, 64, 2705-2711.	0.9	17
255	Can Petoâ€™s paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. BMC Cancer, 2015, 15, 792.	2.6	17
256	The Impact of Tumor Nitric Oxide Production on VEGFA Expression and Tumor Growth in a Zebrafish Rat Glioma Xenograft Model. PLoS ONE, 2015, 10, e0120435.	2.5	17
257	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer Journal (Sudbury, Mass), 2018, 24, 153-162.	2.0	17
258	Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. Annals of the Rheumatic Diseases, 2000, 59, 146-148.	0.9	16
259	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer Journal, 2018, 8, 114.	6.2	16
260	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. Npj Precision Oncology, 2020, 4, 27.	5.4	16
261	Cytokine-like protein 1â€“induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood, 2021, 137, 3390-3402.	1.4	16
262	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. International Journal of Cancer, 1994, 58, 85-94.	5.1	15
263	Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplantation, 1997, 20, 63-65.	2.4	15
264	Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1998, 21, 943-946.	2.4	15
265	Analyzing Markers of Apoptosis In Vitro. , 2004, 281, 313-332.		15
266	Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia. Journal of Molecular Medicine, 2019, 97, 633-645.	3.9	15
267	The role of host environment in cancer evolution. Evolutionary Applications, 2020, 13, 1756-1770.	3.1	15
268	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. International Journal of Cancer, 1995, 63, 268-275.	5.1	14
269	Trefoil Factor TFF1-Induced Protection of Conjunctival Cells from Apoptosis at Premitochondrial and Postmitochondrial Levels. , 2008, 49, 3790.		14
270	Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?. Best Practice and Research in Clinical Haematology, 2013, 26, 387-400.	1.7	14

#	Article	IF	Citations
271	Epigenetic Control of NF-ÎºB-Dependent FAS Gene Transcription during Progression of Myelodysplastic Syndromes. Molecular Cancer Research, 2013, 11, 724-735.	3.4	14
272	Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood Cancer Journal, 2017, 7, e562-e562.	6.2	14
273	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	2.8	14
274	Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells. Oncotarget, 2015, 6, 10267-10283.	1.8	14
275	New insights into the kinetic resistance to anticancer agents. Cytotechnology, 1998, 27, 225-235.	1.6	13
276	An atypical caspase-independent death pathway for an immunogenic cancer cell line. Oncogene, 2002, 21, 6091-6100.	5.9	13
277	LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. Blood, 2003, 101, 194-201.	1.4	13
278	Identification of a functional DNA binding site for the SREBP-1c transcription factor in the first intron of the human caspase-2 gene. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 1-5.	2.4	13
279	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal, 2011, 1, e7-e7.	6.2	13
280	MUB40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. Cell Chemical Biology, 2018, 25, 483-493.e9.	5.2	13
281	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. Haematologica, 2020, 105, 112-123.	3.5	13
282	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. Autoimmunity Reviews, 2020, 19, 102446.	5.8	13
283	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, 2022, 140, 1408-1418.	1.4	13
284	Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish. Immunogenetics, 2010, 62, 681-699.	2.4	12
285	Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNÎ± treatment. Leukemia, 2014, 28, 460-463.	7.2	12
286	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene, 2020, 39, 5323-5337.	5.9	12
287	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	1.8	12
288	H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway. Oncotarget, 2015, 6, 6877-6886.	1.8	12

#	Article	IF	Citations
289	Systemic lupus erythematosus occurring in a patient with multiple myeloma. Arthritis and Rheumatism, 1986, 29, 933-934.	6.7	11
290	New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. Cancer Genetics and Cytogenetics, 1992, 60, 90-92.	1.0	11
291	Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. Cancer Gene Therapy, 2008, 15, 742-749.	4.6	11
292	Differential Effects of CSF-1R D802V and KIT D816V Homologous Mutations on Receptor Tertiary Structure and Allosteric Communication. PLoS ONE, 2014, 9, e97519.	2.5	11
293	Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease. JCI Insight, 2017, 2, e90531.	5.0	11
294	Re-examining the role of cytochrome c in cell death. Nature Genetics, 2008, 40, 379-380.	21.4	10
295	PKC zeta controls DNA topoisomeraseâ€dependent human caspaseâ€2 preâ€mRNA splicing. FEBS Letters, 2008, 582, 372-378.	2.8	10
296	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. PLoS ONE, 2015, 10, e0126526.	2.5	10
297	The guardians of inherited oncogenic vulnerabilities. Evolution; International Journal of Organic Evolution, 2016, 70, 1-6.	2.3	10
298	Using healthcare claims data to analyze the prevalence of BCRâ€ABLâ€positive chronic myeloid leukemia in France: A nationwide populationâ€based study. Cancer Medicine, 2019, 8, 3296-3304.	2.8	10
299	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp>â€2 pandemic. American Journal of Hematology, 2020, 95, E203-E208.	4.1	10
300	Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting. European Journal of Health Economics, 2021, 22, 855-864.	2.8	10
301	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 2739-2751.	7.2	10
302	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. Leukemia, 2002, 16, 1154-1159.	7.2	9
303	Trefoil factor family mRNA and protein expression in pterygium. International Journal of Oncology, 2005, 27, 997.	3.3	9
304	Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia. Clinical Cancer Research, 2016, 22, 3707-3709.	7.0	9
305	Heterogenous Expression of CD15 in Acute Lymphoblastic Leukemia: A Study of Ten Anti-CD15 Monoclonal Antibodies in 158 Patients. Leukemia and Lymphoma, 1997, 25, 135-143.	1.3	8
306	Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. Leukemia, 2002, 16, 1569-1570.	7.2	8

#	Article	IF	Citations
307	A role for PKCÎ¶ in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. Molecular Cancer Therapeutics, 2005, 4, 1457-1464.	4.1	8
308	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. Stem Cells, 2015, 33, 2887-2892.	3.2	8
309	Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. PLoS ONE, 2016, 11, e0160165.	2.5	8
310	Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 147-154.	7.4	8
311	A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease. Human Molecular Genetics, 2017, 26, 4680-4688.	2.9	8
312	The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment. Frontiers in Molecular Neuroscience, 2017, 10, 246.	2.9	8
313	High sensitivity of the Hematoflowâ„¢ solution for chronic myelomonocytic leukemia screening. Cytometry Part B - Clinical Cytometry, 2018, 94, 814-817.	1.5	8
314	Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?. Best Practice and Research in Clinical Haematology, 2020, 33, 101134.	1.7	8
315	Tumor Cell Resistance to DNA-Damaging Agents: From Apoptosis to Neiosis. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 461-463.	7.0	8
316	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes. Communications Biology, 2022, 5, 110.	4.4	8
317	Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 209-211.	0.4	7
318	Ageing and cancer: a research gap to fill. Molecular Oncology, 2022, 16, 3220-3237.	4.6	7
319	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. EBioMedicine, 2022, 80, 104077.	6.1	7
320	Itraconazole as Salvage Therapy in Invasive Pulmonary Aspergillosis Occurring during Amphotericin B Therapy in Neutropenic Patients. Chemotherapy, 1992, 38, 50-51.	1.6	6
321	Various functions of caspases in hematopoiesis. Frontiers in Bioscience - Landmark, 2009, Volume, 2358.	3.0	6
322	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. Leukemia and Lymphoma, 2018, 59, 1742-1745.	1.3	6
323	UBA1 gene mutation in giant cell arteritis. Clinical Rheumatology, 2022, 41, 1257-1259.	2.2	6
324	BCR-ABL Fails to Inhibit Apoptosis in U937 Myelomonocytic Cells Expressing a Carboxyl-Terminal Truncated Stat5. Leukemia and Lymphoma, 2001, 42, 445-455.	1.3	5

#	Article	IF	Citations
325	Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. Leukemia Research, 2017, 55, 58-64.	0.8	5
326	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	6.2	5
327	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	1.4	5
328	Prognostic Relevance of Surface Markers in Adult de novo Acute Myeloblasts Leukemias: A Prospective Study of the Groupe d'Etude Immunologique des Leucemies (G.E.I.L.). Leukemia and Lymphoma, 1994, 13, 7-10.	1.3	4
329	FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. , 1999, 82, 359-367.		4
330	A role for the transcription intermediary factor 2 in zebrafish myelopoiesis. Experimental Hematology, 2008, 36, 559-567.	0.4	4
331	Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations. Cellular and Molecular Life Sciences, 2012, 69, 2853-2861.	5.4	4
332	Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2503-2505.	1.3	4
333	No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19. OncoImmunology, 2020, 9, 1857112.	4.6	4
334	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. Blood, 1998, 91, 2415-2422.	1.4	4
335	ASSOCIATION OF A CHROMOSOMAL 9.12 TRANSLOCATION WITH B CELL PRECURSOR LYMPHOBLASTIC BLAST CRISIS OF A Ph+ CHRONIC MYELOGENOUS LEUKAEMIA. British Journal of Haematology, 1989, 72, 106-108.	2.5	3
336	Diagnostic value of serum IL-6 level in monoclonal gammopathies. British Journal of Haematology, 1995, 89, 243-249.	2.5	3
337	CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS. , 2002, , 55-76.		3
338	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 276.	16.8	3
339	When monocyte life hangs by a thread. Blood, 2012, 119, 2699-2700.	1.4	3
340	Tubulinâ€targeting agent combination therapies: dosing schedule could matter. British Journal of Pharmacology, 2013, 168, 1555-1557.	5.4	3
341	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. Leukemia and Lymphoma, 2017, 58, 2875-2879.	1.3	3
342	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. Leukemia, 2021, 35, 893-896.	7.2	3

#	Article	IF	Citations
343	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. Blood, 2010, 116, 3997-3997.	1.4	3
344	Reprogramming monocyte-derived macrophages through caspase inhibition. OncoImmunology, 2022, 11, 2015859.	4.6	3
345	Editorial: The emerging specificities of interleukin-34. Journal of Leukocyte Biology, 2014, 95, 3-5.	3.3	2
346	Chronic Myelomonocytic Leukemia Prognostic Classification and Management: Evidence Base and Current Practice. Current Hematologic Malignancy Reports, 2014, 9, 301-310.	2.3	2
347	Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. Blood, 2020, 136, 15-16.	1.4	2
348	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 109-109.	1.4	2
349	Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia. International Journal of Hematologic Oncology, 2012, 1, 147-158.	1.6	1
350	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
351	French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hematologie, 2015, 21, 28-45.	0.0	1
352	A Caspase-7/NOX2 Axis Regulates the Migration of Monocytes in Response to Colony-Stimulating Factor-1. SSRN Electronic Journal, 0, , .	0.4	1
353	IMMUNE MECHANISMS IN HIV-RELATED NEUROPATHIES. Lancet, The, 1989, 334, 812-813.	13.7	0
354	SERUM IL-6 CONCENTRATIONS IN LYMPHOMAS. British Journal of Haematology, 1995, 90, 732-732.	2.5	0
355	Implications physiopathologiques des altÃ©rations des gÃ¨nes impliquÃ©s dans la rÃ©gulation de la mort cellulaire. Medecine/Sciences, 2002, 18, 861-873.	0.2	0
356	C020 Prevalence of TET2 mutations in MDS. Leukemia Research, 2009, 33, S43-S44.	0.8	0
357	Recent advances in chronic myelomonocytic leukemia. Hematologie, 2012, 18, 24-36.	0.0	0
358	SFP CO-61 - Etude du rÃ1e de lâ€™interfÃ©ron-gamma dans le syndrome hÃ©mophagocytaire des hÃ©mopathies lymphoÃ¯des. Archives De Pediatrie, 2014, 21, 639.	1.0	0
359	Does being overweight contribute to longer survival rates in myelodysplastic syndrome?. Haematologica, 2018, 103, 559-560.	3.5	0
360	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0

#	Article	IF	Citations
361	Chronic Myelomonocytic Leukemia (CMML). Hematologic Malignancies, 2018, , 65-79.	0.2	0
362	Tracking chronic myelomonocytic leukaemia diversity at the single cell level. EBioMedicine, 2020, 59, 102935.	6.1	0
363	Chronic Myelomonocytic Leukemia Gold Jubilee. Hemato, 2021, 2, 403-428.	0.6	0
364	Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes.. Blood, 2006, 108, 2638-2638.	1.4	0
365	Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum.. Blood, 2007, 110, 3346-3346.	1.4	0
366	New insights into the kinetic resistance to anticancer agents. , 1998, , 225-235.		0
367	HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?. Blood, 2015, 126, 671-671.	1.4	0
368	Topoisomerase I Poisons and Apoptotic Topoisomerase I-DNA Complexes. , 2007, , 383-406.		0